226 related articles for article (PubMed ID: 32356145)
1. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.
Carbone EA; Caroleo M; Rania M; Calabrò G; Staltari FA; de Filippis R; Aloi M; Condoleo F; Arturi F; Segura-Garcia C
Eat Weight Disord; 2021 Apr; 26(3):779-788. PubMed ID: 32356145
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
Grilo CM; Lydecker JA; Morgan PT; Gueorguieva R
Clin Ther; 2021 Jan; 43(1):112-122.e1. PubMed ID: 33218742
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Guerdjikova AI; Walsh B; Shan K; Halseth AE; Dunayevich E; McElroy SL
Adv Ther; 2017 Oct; 34(10):2307-2315. PubMed ID: 28918581
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial.
Grilo CM; Lydecker JA; Gueorguieva R
Psychol Med; 2023 Dec; 53(16):7775-7784. PubMed ID: 37366017
[TBL] [Abstract][Full Text] [Related]
5. Influence of
Carbone EA; Caroleo M; Rania M; de Filippis R; Condoleo F; Catalano F; Aloi M; De Fazio P; Arturi F; Hribal ML; Fiorentino TV; Segura-Garcia C
Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38398053
[No Abstract] [Full Text] [Related]
6. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
Grilo CM; Lydecker JA; Fineberg SK; Moreno JO; Ivezaj V; Gueorguieva R
Am J Psychiatry; 2022 Dec; 179(12):927-937. PubMed ID: 36285406
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.
Grilo CM; Lydecker JA; Jastreboff AM; Pittman B; McKee SA
Obesity (Silver Spring); 2023 Nov; 31(11):2762-2773. PubMed ID: 37751990
[TBL] [Abstract][Full Text] [Related]
8. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
White MA; Grilo CM
J Clin Psychiatry; 2013 Apr; 74(4):400-6. PubMed ID: 23656848
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
Billes SK; Sinnayah P; Cowley MA
Pharmacol Res; 2014 Jun; 84():1-11. PubMed ID: 24754973
[TBL] [Abstract][Full Text] [Related]
10. Treatment of binge eating disorder.
Wilson GT
Psychiatr Clin North Am; 2011 Dec; 34(4):773-83. PubMed ID: 22098803
[TBL] [Abstract][Full Text] [Related]
11. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
[TBL] [Abstract][Full Text] [Related]
12. Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
Halseth A; Shan K; Walsh B; Gilder K; Fujioka K
Obesity (Silver Spring); 2017 Feb; 25(2):338-345. PubMed ID: 28026920
[TBL] [Abstract][Full Text] [Related]
13. Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.
Calandra C; Russo RG; Luca M
Psychiatr Q; 2012 Jun; 83(2):177-85. PubMed ID: 21927936
[TBL] [Abstract][Full Text] [Related]
14. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
[TBL] [Abstract][Full Text] [Related]
15. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as.
Grilo CM; White MA
Behav Res Ther; 2013 Mar; 51(3):167-75. PubMed ID: 23376451
[TBL] [Abstract][Full Text] [Related]
16. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.
Pi-Sunyer X; Apovian CM; McElroy SL; Dunayevich E; Acevedo LM; Greenway FL
Int J Obes (Lond); 2019 Oct; 43(10):2085-2094. PubMed ID: 30664661
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with naltrexone and bupropion for obesity.
Billes SK; Greenway FL
Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
[TBL] [Abstract][Full Text] [Related]
18. Reactive hypoglycemia in binge eating disorder, food addiction, and the comorbid phenotype: unravelling the metabolic drive to disordered eating behaviours.
Rania M; Caroleo M; Carbone EA; Ricchio M; Pelle MC; Zaffina I; Condoleo F; de Filippis R; Aloi M; De Fazio P; Arturi F; Segura-Garcia C
J Eat Disord; 2023 Sep; 11(1):162. PubMed ID: 37726785
[TBL] [Abstract][Full Text] [Related]
19. Virtual reality for enhancing the cognitive behavioral treatment of obesity with binge eating disorder: randomized controlled study with one-year follow-up.
Cesa GL; Manzoni GM; Bacchetta M; Castelnuovo G; Conti S; Gaggioli A; Mantovani F; Molinari E; Cárdenas-López G; Riva G
J Med Internet Res; 2013 Jun; 15(6):e113. PubMed ID: 23759286
[TBL] [Abstract][Full Text] [Related]
20. An Evaluation of the Italian Version of the Yale Food Addiction Scale in Obese Adult Inpatients Engaged in a 1-Month-Weight-Loss Treatment.
Ceccarini M; Manzoni GM; Castelnuovo G; Molinari E
J Med Food; 2015 Nov; 18(11):1281-7. PubMed ID: 26267366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
